Combretastatin A-1 is primarily used in medical research for its potential as an anticancer agent. It works by targeting and disrupting the blood vessels that supply tumors, effectively cutting off their nutrient and oxygen supply. This process, known as vascular disruption, can lead to the shrinkage or death of cancer cells. It is often studied in combination with other therapies, such as chemotherapy or radiation, to enhance its effectiveness. Additionally, it is being explored for its role in treating eye diseases like macular degeneration due to its ability to inhibit abnormal blood vessel growth. Research is ongoing to better understand its mechanisms and optimize its use in clinical settings.